| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Anti-VEGFR, PDGFR, and CSF1R tyrosine kinase inhibitor CM082 (X-82) in combination with everolimus for treatment of metastatic renal cell carcinoma: a phase 1 clinical trial
|
Yan, Xieqiao
|
|
2017
|
18 |
S1 |
p. S8-
1 p.
|
artikel
|
| 2 |
Chimeric antigen receptor-modified T cells directed against CD19 in patients with relapsed or refractory CD19-positive B-cell lymphomas: interim analysis of a phase 1 study
|
Ying, Zhitao
|
|
2017
|
18 |
S1 |
p. S9-
1 p.
|
artikel
|
| 3 |
Comparison between sublobar resection and lobectomy for the surgical treatment of elderly patients with early stage non-small-cell lung cancer (STEPS): an open label, multicentre, non-inferiority, randomised, phase 3 clinical trial
|
Yang, Fan
|
|
2017
|
18 |
S1 |
p. S2-
1 p.
|
artikel
|
| 4 |
Concurrent chemoradiotherapy of capecitabine with or without oxaliplatin versus cisplatin with fluorouracil for treatment of squamous oesophageal cancer in Chinese patients (CRTCOESC): an interim report of a randomised, open-label, multicentre trial
|
Jia, Ruinuo
|
|
2017
|
18 |
S1 |
p. S4-
1 p.
|
artikel
|
| 5 |
Continuous intravenous infusion of recombinant human endostatin combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer (HELPER): a phase 2, multicentre study
|
Zhai, Yirui
|
|
2017
|
18 |
S1 |
p. S11-
1 p.
|
artikel
|
| 6 |
Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study
|
Han, Baohui
|
|
2017
|
18 |
S1 |
p. S3-
1 p.
|
artikel
|
| 7 |
Palbociclib plus letrozole as first-line treatment for ER-positive and HER2-negative advanced breast cancer in Chinese women: a phase 1 study
|
Li, Huiping
|
|
2017
|
18 |
S1 |
p. S7-
1 p.
|
artikel
|
| 8 |
Personalised peptide vaccination combined with radiotherapy for patients with advanced hepatocellular carcinoma: a phase 1 study
|
Shen, Jie
|
|
2017
|
18 |
S1 |
p. S5-
1 p.
|
artikel
|
| 9 |
Recombinant humanised anti-PD-1 monoclonal antibody (JS001) treatment for patients with refractory or metastatic nasopharyngeal carcinoma: preliminary results of an open-label, phase 1b/2, clinical study
|
Xu, Ruihua
|
|
2017
|
18 |
S1 |
p. S1-
1 p.
|
artikel
|
| 10 |
Response-adapted therapy for limited stage diffuse large B-cell lymphoma based on interim PET-CT: preliminary results of a phase 2 study
|
Lv, Fangfang
|
|
2017
|
18 |
S1 |
p. S10-
1 p.
|
artikel
|
| 11 |
Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: a phase 2 trial
|
Wang, Xin
|
|
2017
|
18 |
S1 |
p. S6-
1 p.
|
artikel
|
Tijdschrift beschrijving